( ts on XYOTAX had longer median survival...)XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer,Health

ts on XYOTAX had longer median survival (220 days vs. 198 days; p=0.686) with significantly fewer adverse events (all grades; 2.0 vs. 3.0; p=0.011), despite receiving more chemotherapy cycles (3.9 vs. 3.4; p=0.007). In addition, XYOTAX patients had fewer outpatient visits (0.6 vs. 1.7; p < 0.001), required fewer diagnostic tests (0.6 vs. 1.9; p < 0.001), and were on non-chemotherapy medications for a shorter period of time (64.4 days vs. 91.2 days; p < 0.001). The difference in the number of hospitalizations or length of hospital stays was not statistically significant.

The total average cost of treatment reported, excluding drug costs, was lower for XYOTAX patients ($2,518 per patient) than patients on the control arm ($4,834 per patient). Costs included outpatient visits ($34 vs. $78; p=0.014), non-chemotherapy medications ($717 vs. $911; p < 0.001), chemotherapy administration ($1,557 vs. $3,601; p < 0.001), and in-patient stays ($210 vs. $244; p=0.794) per patient.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells m
'"/>

Page: 1 2 3 4
Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
8. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
9. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
10. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
11. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression